Primary Myelofibrosis Global Market Report 2026

Primary myelofibrosis (PMF) is a rare, long-term bone marrow disorder marked by the excessive development of fibrous scar tissue within the bone marrow. This scarring interferes with normal blood cell formation, resulting in conditions such as anemia, weakness, fatigue, and enlargement of the spleen (splenomegaly). PMF is classified as a type of myeloproliferative neoplasm (MPN) and may also cause symptoms including night sweats, weight loss, and bone pain.

The main types of primary myelofibrosis include spinocerebellar primary myelofibrosis, primary myelofibrosis-telangiectasia, episodic primary myelofibrosis, and other variants. Services related to the condition include diagnosis and treatment, while medications are offered in multiple dosage forms such as solid, liquid, and other formulations to meet varying patient requirements. The disease affects all age groups, including adults, children, and the elderly, and is managed across different end-user settings such as hospitals, clinics, and other healthcare facilities.

Tariffs have influenced the primary myelofibrosis market by increasing the cost of imported diagnostic equipment, medications, and laboratory reagents. Segments such as targeted therapies and advanced diagnostic tools are most affected, particularly in regions like North America and Asia-Pacific, where import reliance is high. This has led to higher treatment costs and limited accessibility in certain regions. On the positive side, tariffs are encouraging local production, domestic R&D investment, and the development of cost-effective treatment alternatives.

The primary myelofibrosis market research report is one of a series of new reports from The Business Research Company that provides primary myelofibrosis market statistics, including primary myelofibrosis industry global market size, regional shares, competitors with a primary myelofibrosis market share, detailed primary myelofibrosis market segments, market trends and opportunities, and any further data you may need to thrive in the primary myelofibrosis industry. This primary myelofibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The primary myelofibrosis market size has grown strongly in recent years. It will grow from $0.84 billion in 2025 to $0.9 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to limited therapeutic options, delayed diagnosis and misdiagnosis, low disease awareness, reliance on conventional treatments, small patient population.

The primary myelofibrosis market size is expected to see strong growth in the next few years. It will grow to $1.14 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to development of novel targeted therapies, increasing clinical trial activities, advancements in genetic and molecular diagnostics, growing investment in hematology research, rising adoption of personalized medicine. Major trends in the forecast period include rising awareness and early diagnosis of primary myelofibrosis, growth in targeted therapies and personalized treatment approaches, increased adoption of advanced diagnostic tools, expansion of clinical trials and research activities, focus on patient support programs and disease management.

The rising prevalence of myelofibrosis is anticipated to drive the growth of the primary myelofibrosis market in the coming years. Myelofibrosis is a rare form of bone marrow cancer that interferes with normal blood cell production, causing extensive scarring of the bone marrow and leading to severe anemia, fatigue, weakness, and enlargement of the spleen. The growing prevalence of myelofibrosis is largely attributed to an aging population, as the disease most frequently affects individuals over 60 years of age, and increased life expectancy has resulted in a greater number of diagnosed cases. The increasing prevalence of myelofibrosis supports improved management of primary myelofibrosis by stimulating research efforts, enabling earlier diagnosis, expanding available treatment options, and encouraging the development of better clinical guidelines and specialized care. For instance, in November 2024, according to a report published by the National Institute for Health and Care Excellence, a UK-based independent executive non-departmental public body, myelofibrosis had a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. Therefore, the increasing prevalence of myelofibrosis is driving the growth of the primary myelofibrosis market.

Major companies operating in the primary myelofibrosis market are concentrating on the development of innovative therapies, such as Janus kinase 2 (JAK2) inhibiting tablets, to enhance symptom management and slow disease progression. JAK2 inhibiting tablets are oral drugs that block the activity of the JAK2 enzyme, which plays a key role in the abnormal signaling pathways responsible for excessive blood cell production in primary myelofibrosis. These medications help decrease spleen enlargement, relieve symptoms such as fatigue and bone pain, and delay disease progression. For example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, introduced Omjjara (momelotinib), a new therapy for myelofibrosis. The drug was approved by South Korea's Ministry of Food and Drug Safety for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara is an oral treatment that inhibits Janus kinases (JAK1 and JAK2) as well as activin A receptor type 1 (ACVR1), effectively addressing symptoms such as anemia, splenomegaly, and fatigue. Its approval was supported by clinical trial results demonstrating meaningful improvements in anemia, spleen size, and overall symptom burden compared with existing therapies.

In September 2025, GlaxoSmithKline plc (GSK), a UK-based biopharmaceutical company, entered into a partnership with the pan-Canadian Pharmaceutical Alliance (pCPA) to expand public access to Ojjaara in Canada. Through this collaboration, the letter of intent aims to support reimbursement discussions and enhance the availability of Ojjaara for adults with myelofibrosis who suffer from moderate to severe anemia. The pan-Canadian Pharmaceutical Alliance (pCPA) is a Canada-based collaborative organization that negotiates drug pricing on behalf of provincial and territorial public drug plans.

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the primary myelofibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary myelofibrosis market consists of revenues earned by entities by providing services such as diagnosis services, medical consultations, treatment services, monitoring and follow-up and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary myelofibrosis (PMF) market also includes sales of products including ruxolitinib (Jakafi or Jakavi), erythropoiesis-stimulating agents (ESAs), hydroxyurea, bone marrow or stem cell transplant kits and iron supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Myelofibrosis Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses primary myelofibrosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary myelofibrosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The primary myelofibrosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Spinocerebellar Primary Myelofibrosiss; Primary Myelofibrosis-Telangiectasia; Episodic Primary Myelofibrosis; Other Types
• 2) By Services: Treatment; Diagnosis
• 3) By Dosage Forms: Solid; Liquids; Other Dosage Forms
• 4) By Age: Adult; Child; Geriatric
• 5) By End User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis; Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis; Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations
• 2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis; Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis; Ocular Telangiectasia-Associated Myelofibrosis
• 3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes; Periodic Cytopenia With Fibrosis Flare; Cyclical Myelofibrosis In Autoimmune Disorders
• 4) By Other Types: Familial Primary Myelofibrosis; Idiopathic Myelofibrosis; Therapy-Related Primary Myelofibrosis; Juvenile Primary Myelofibrosis
• Companies Mentioned: Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Sumitomo Pharma Oncology Inc.; Incyte Corporation; Nippon Shinyaku Co. Ltd.; MorphoSys AG; Keros Therapeutics Inc.; Geron Corporation; Lynk Pharmaceuticals Co. Ltd.; Pharmaxis Ltd; Kartos Therapeutics Inc.; Disc Medicine Inc.; Galecto Inc.; Cellenkos Inc.; Chia Tai Tianqing Pharmaceutical Group Co. Ltd.; Taiga Biotechnologies Inc.; Suzhou Zelgen Biopharmaceuticals Co. Ltd.; Telios Pharma Inc.; Samus Therapeutics Inc.; Jacobio Pharmaceuticals Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.